drugset / Trial / NCT01012973

Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)

NCT01012973

Phase 3 Completed 177 enrolled Bayer Regeneron Pharmaceuticals · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

To determine the efficacy of vascular endothelial growth factor (VEGF) Trap-Eye injected into the eye on vision function in subjects with macular edema as a consequence of central retinal vein occlusion

Timeline

Start
2009-10
Primary completion
2011-02
Completion
2012-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Aflibercept Protein / enzyme biologic 2 mg Intravitreal